These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24619209)

  • 1. Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis.
    Gheuens E; Daelemans R; Mesens S
    Invest Radiol; 2014 Aug; 49(8):505-8. PubMed ID: 24619209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability.
    Tombach B; Bremer C; Reimer P; Matzkies F; Schaefer RM; Ebert W; Geens V; Eisele J; Heindel W
    AJR Am J Roentgenol; 2002 Jan; 178(1):105-9. PubMed ID: 11756100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
    Fretellier N; Salhi M; Schroeder J; Siegmund H; Chevalier T; Bruneval P; Jestin-Mayer G; Delaloge F; Factor C; Mayer JF; Fabicki JM; Robic C; Bonnemain B; Idée JM; Corot C
    Eur J Pharm Sci; 2015 May; 72():46-56. PubMed ID: 25736527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies.
    Balassy C; Roberts D; Miller SF
    Pediatr Radiol; 2015 Nov; 45(12):1831-41. PubMed ID: 26045036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
    Lancelot E
    Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.
    Reilly RF
    Clin J Am Soc Nephrol; 2008 May; 3(3):747-51. PubMed ID: 18287249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function.
    Bradu A; Penescu M; Pitrou C; Hao J; Bourrinet P
    Invest Radiol; 2021 Aug; 56(8):486-493. PubMed ID: 34197356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
    Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
    Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis].
    Krahe T; Götz R; Lackner K; Haustein J; Klemenz U; Landwehr P; Heidbreder E; Schuhmann-Giampieri G
    Rofo; 1992 Jun; 156(6):523-6. PubMed ID: 1617171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
    Young LK; Matthew SZ; Houston JG
    Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dialyzability of gadodiamide in hemodialysis patients.
    Saitoh T; Hayasaka K; Tanaka Y; Kuno T; Nagura Y
    Radiat Med; 2006 Jul; 24(6):445-51. PubMed ID: 16958426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
    Perazella MA
    Clin J Am Soc Nephrol; 2008 May; 3(3):649-51. PubMed ID: 18385396
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of Gadodiamide and Gadoteric Acid on Rat Kidneys: A Comparative Study.
    Celiker FB; Tumkaya L; Mercantepe T; Beyazal M; Turan A; Beyazal Polat H; Suzan ZT; Inecikli MF; Akyildiz K; Yilmaz A
    J Magn Reson Imaging; 2019 Feb; 49(2):382-389. PubMed ID: 30209850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
    Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
    Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clearance of gadolinium contrast agent by hemodialysis: in vitro and clinical studies].
    Katagiri K; Okada S; Kumazaki T; Tsuboi N
    Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Nov; 58(13):739-44. PubMed ID: 9866990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A
    J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.